User profiles for Robert S. Hogg
 | Robert HoggFaculty of Health Sciences, Simon Fraser University Verified email at sfu.ca Cited by 62134 |
Improved survival among HIV-infected individuals following initiation of antiretroviral therapy
RS Hogg, KV Heath, B Yip, KJP Craib… - Jama, 1998 - jamanetwork.com
Context.—Clinical trials have established the efficacy of antiretroviral therapy with double-
and triple-drug regimens for individuals infected with the human immunodeficiency virus (HIV)…
and triple-drug regimens for individuals infected with the human immunodeficiency virus (HIV)…
Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy
ContextCurrent recommendations for initiation of antiretroviral therapy in patients infected
with human immunodeficiency virus type 1 (HIV) are based on CD4 T-lymphocyte cell counts …
with human immunodeficiency virus type 1 (HIV) are based on CD4 T-lymphocyte cell counts …
Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up
RS Hogg, K Heath, D Bangsberg, B Yip, N Press… - Aids, 2002 - journals.lww.com
Results As of 30 September 2000, 106 subjects had died. Cumulative mortality was 3.9%(±0.5%)
at 12 months. In a multivariate model, after controlling for other variables that were …
at 12 months. In a multivariate model, after controlling for other variables that were …
Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens
RS Hogg, B Yip, C Kully, KJP Craib… - Cmaj, 1999 - Can Med Assoc
BACKGROUND: The efficacy of triple-drug antiretroviral regimens in the treatment of patients
infected with HIV has been established in several randomized clinical trials. However, the …
infected with HIV has been established in several randomized clinical trials. However, the …
Decline in deaths from AIDS due to new antiretrovirals
RS Hogg, MV O'Shaughnessy, N Gataric, B Yip… - The Lancet, 1997 - thelancet.com
We determined whether availability of new antiretroviral treatments has had any impact on
the rate of death for people with HIV-1 infection. Distribution of antiretroviral drugs in British …
the rate of death for people with HIV-1 infection. Distribution of antiretroviral drugs in British …
Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies
…, AC Justice, S Staszewski, C Leport, RS Hogg… - The Lancet, 2002 - thelancet.com
Background Insufficient data are available from single cohort studies to allow estimation of
the prognosis of HIV-1 infected, treatment-naive patients who start highly active antiretroviral …
the prognosis of HIV-1 infected, treatment-naive patients who start highly active antiretroviral …
[HTML][HTML] Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada
Background Combination antiretroviral therapy (ART) has significantly increased survival
among HIV-positive adults in the United States (US) and Canada, but gains in life expectancy …
among HIV-positive adults in the United States (US) and Canada, but gains in life expectancy …
[HTML][HTML] Effect of early versus deferred antiretroviral therapy for HIV on survival
…, MS Saag, AC Justice, RS Hogg… - … England Journal of …, 2009 - Mass Medical Soc
Background The optimal time for the initiation of antiretroviral therapy for asymptomatic patients
with human immunodeficiency virus (HIV) infection is uncertain. Methods We conducted …
with human immunodeficiency virus (HIV) infection is uncertain. Methods We conducted …
[HTML][HTML] Emergence of drug resistance is associated with an increased risk of death among patients first starting HAART
Background The impact of the emergence of drug-resistance mutations on mortality is not
well characterized in antiretroviral-naïve patients first starting highly active antiretroviral …
well characterized in antiretroviral-naïve patients first starting highly active antiretroviral …
Effect of Medication Adherence on Survival of HIV-Infected Adults Who Start Highly Active Antiretroviral Therapy When the CD4+ Cell Count Is 0.200 to 0.350 × 109 …
E Wood, RS Hogg, B Yip, PR Harrigan… - Annals of internal …, 2003 - acpjournals.org
Background: The safety of delaying highly active antiretroviral therapy (HAART) in HIV-infected
patients is uncertain when the CD4+ cell count declines below 0.350 × 10 9 cells/L. …
patients is uncertain when the CD4+ cell count declines below 0.350 × 10 9 cells/L. …
